{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:13:53Z","timestamp":1768684433949,"version":"3.49.0"},"reference-count":53,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The selection of the best alternative for Enterococcus faecalis infective endocarditis (IE) continuation treatment in the outpatient setting is still challenging. Three databases were searched, reporting antibiotic therapies against E. faecalis IE in or suitable for the outpatient setting. Articles the results of which were identified by species and treatment regimen were included. The quality of the studies was assessed accordingly with the study design. Data were extracted and synthesized narratively. In total, 18 studies were included. The treatment regimens reported were classified regarding the main antibiotic used as regimen, based on Aminoglycosides, dual \u03b2-lactam, teicoplanin, daptomycin or dalbavancin or oral therapy. The regimens based on aminoglycosides and dual \u03b2-lactam combinations are the treatment alternatives which gather more evidence regarding their efficacy. Dual \u03b2-lactam is the preferred option for high level aminoglycoside resistance strains, and for to its reduced nephrotoxicity, while its adaptation to the outpatient setting has been poorly documented. Less evidence supports the remaining alternatives, but many of them have been successfully adapted to outpatient care. Teicoplanin and dalbavancin as well as oral therapy seem promising. Our work provides an extensive examination of the potential alternatives to E. faecalis IE useful for outpatient care. However, the insufficient evidence hampers the attempt to give a general recommendation.<\/jats:p>","DOI":"10.3390\/antibiotics9100657","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T09:41:01Z","timestamp":1601458861000},"page":"657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives"],"prefix":"10.3390","volume":"9","author":[{"given":"Laura","family":"Herrera-Hidalgo","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Farmacia, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00edstides","family":"de Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-527X","authenticated-orcid":false,"given":"Luis","family":"L\u00f3pez-Cortes","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen Macarena\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Luque-M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"L\u00f3pez-Cortes","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"},{"name":"Infecci\u00f3n por el VIH y farmacocin\u00e9tica de antivirals, Instituto de Biomedicina de Sevilla (IBiS), Antonio Maura Montaner Street s\/n, 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Gil-Navarro","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Farmacia, Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Instituto de Biomedicina de Sevilla (IBiS), 41009 Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jacc.2017.10.005","article-title":"The Evolving Nature of Infective Endocarditis in Spain","volume":"70","author":"Olmos","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","first-page":"728","article-title":"Epidemiology of Infective Endocarditis in Spain in the Last 20 Years","volume":"66","author":"Mas","year":"2013","journal-title":"Rev. Espa\u00f1ola Cardiol. (Engl. Ed.)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/cid\/ciy064","article-title":"A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis","volume":"67","author":"Beganovic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00058-18","DOI":"10.1128\/CMR.00058-18","article-title":"The Enterococcus: A Model of Adaptability to Its Environment","volume":"32","author":"Rice","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1574-6968.2006.00112.x","article-title":"Relationship between biofilm formation, the enterococcal surface protein (Esp) and gelatinase in clinical isolates of Enterococcus faecalis and Enterococcus faecium","volume":"256","author":"Rosa","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0213-005X(11)70045-3","article-title":"Enterococcus: Resistencias fenot\u00edpicas y genot\u00edpicas y epidemiolog\u00eda en Espa\u00f1a","volume":"29","author":"Cercenado","year":"2011","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/ciz030","article-title":"Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort","volume":"69","author":"Llopis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","unstructured":"Shah, A.B., and Norris, A.H. (2016). Handbook of Outpatient Parenteral Antimicrobial Therapy for Infectious Diseases, CRG Publishing, a Division of The Curry Rockefeller Group, LLC, and the Infectious Diseases Society of America. [3rd ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eimc.2018.03.012","article-title":"Executive summary of outpatient parenteral antimicrobial therapy: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases and the Spanish Domiciliary Hospitalisation Society","volume":"37","author":"Aznar","year":"2019","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brown, E., and Gould, F.K. (2020). Oral antibiotics for infective endocarditis: A clinical review. J. Antimicrob. Chemother.","DOI":"10.1093\/jac\/dkaa106"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya","volume":"68","author":"Norris","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dks003","article-title":"On behalf of the BSAC\/BIA OPAT Project Good Practice Recommendations Working Group Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: A consensus statement","volume":"67","author":"Chapman","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/321814","article-title":"Patient Selection Criteria and Management Guidelines for Outpatient Parenteral Antibiotic Therapy for Native Valve Infective Endocarditis","volume":"33","author":"Andrews","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0891-5520(05)70026-X","article-title":"Outpatient Intravenous Antibiotic Therapy for Endocarditis","volume":"12","author":"Rehm","year":"1998","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bjid.2017.06.006","article-title":"Recommendations for outpatient parenteral antimicrobial therapy in Brazil","volume":"21","author":"Oliveira","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_19","first-page":"220","article-title":"Outpatient parenteral antimicrobial therapy inEnterococcus faecalisinfective endocarditis","volume":"43","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/jac\/dku004","article-title":"Efficacy of daptomycin in the treatment of enterococcal endocarditis: A 5 year comparison with conventional therapy","volume":"69","author":"Bermejo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijantimicag.2018.10.003","article-title":"Teicoplanin for treating enterococcal infective endocarditis: A retrospective observational study from a referral centre in Spain","volume":"53","author":"Pigrau","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s15010-019-01290-w","article-title":"Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: A retrospective cohort study","volume":"47","author":"Sommet","year":"2019","journal-title":"Infectction"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/23744235.2019.1672888","article-title":"Treatment of Enterococcus faecalis infective endocarditis with penicillin G plus ceftriaxone","volume":"52","author":"Suzuki","year":"2019","journal-title":"Infect. Dis. (Auckl.)"},{"key":"ref_25","first-page":"1","article-title":"Penicillin as a Potential Agent for Dual Beta-lactam Therapy for Enterococcal Endocarditis","volume":"2019","author":"Tritle","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7326\/0003-4819-146-8-200704170-00008","article-title":"Brief Communication: Treatment of Enterococcus faecalis Endocarditis with Ampicillin plus Ceftriaxone","volume":"146","author":"Len","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"O1075","DOI":"10.1111\/1469-0691.12756","article-title":"Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: From ampicillin plus gentamicin to ampicillin plus ceftriaxone","volume":"20","author":"Pericas","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: A Prospective Study from the International Collaboration on Endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pericas, J.M., Cervera, C., Moreno, A., Garc\u00eda-De-La-M\u00e0ria, C., Almela, M., Falces, C., Quintana, E., Vidal, B., Llopis, J., and Fuster, D. (2018). Outcome of Enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: Preliminary data from a cohort of 78 patients. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196317"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jinf.2018.06.013","article-title":"Comparison of Dual \u03b2-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis","volume":"77","author":"DeSimone","year":"2018","journal-title":"J. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/cid\/cit052","article-title":"Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for TreatingEnterococcus faecalisInfective Endocarditis","volume":"56","author":"Almirante","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40121-019-00261-w","article-title":"Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?","volume":"8","author":"Bassetti","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.112.001170","article-title":"Enterococcus faecalis Infective Endocarditis","volume":"127","author":"Dahl","year":"2013","journal-title":"Circulation"},{"key":"ref_34","first-page":"1","article-title":"DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Vinuesa","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jac\/31.5.755","article-title":"The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria","volume":"31","author":"Presterl","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lebeaux, D., Fern\u00e1ndez-Hidalgo, N., Pilmis, B., Tattevin, P., and Mainardi, J.-L. (2019). Aminoglycosides for infective endocarditis: Time to say goodbye?. Clin. Microbiol. Infect.","DOI":"10.1016\/j.cmi.2019.10.017"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/338233","article-title":"Enterococcal Endocarditis in Sweden, 1995\u20131999: Can Shorter Therapy with Aminoglycosides Be Used?","volume":"34","author":"Olaison","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","first-page":"338","article-title":"Stability of Ampicillin in Normal Saline and Buffered Normal Saline","volume":"20","author":"Maher","year":"2016","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4236\/pp.2012.34063","article-title":"Stability Test of Ampicillin Sodium Solutions in the Accufuser\u00ae Elastomeric Infusion Device Using HPLC: UV Method","volume":"3","author":"Kang","year":"2012","journal-title":"Pharmacol. Pharm."},{"key":"ref_40","first-page":"1","article-title":"Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy","volume":"64","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.43.3.639","article-title":"Efficacy of Ampicillin plus Ceftriaxone in Treatment of Experimental Endocarditis Due to Enterococcus faecalis Strains Highly Resistant to Aminoglycosides","volume":"43","author":"Torres","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijantimicag.2014.03.011","article-title":"In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis","volume":"44","author":"Liao","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-019-00148-4","article-title":"Current Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review","volume":"8","author":"Kobayashi","year":"2019","journal-title":"Cardiol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.athoracsur.2007.02.096","article-title":"Early Switch From Vancomycin to Oral Linezolid for Treatment of Gram-Positive Heart Valve Endocarditis","volume":"84","author":"Colli","year":"2007","journal-title":"Ann. Thorac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1469-0691.2006.01585.x","article-title":"Linezolid therapy for infective endocarditis","volume":"13","author":"Moreno","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fmb-2019-0247","article-title":"Enterococcus faecalis endocarditis: What\u2019s next?","volume":"15","author":"Pericas","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jrsm.1078","article-title":"Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions","volume":"4","author":"Tugwell","year":"2013","journal-title":"Res. Synth. Methods"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sterne, J.A.C., Hern\u00e1n, M.A., Reeves, B.C., Savovi\u0107, J., Berkman, N.D., Viswanathan, M., Henry, D., Altman, D.G., Ansari, M.T., and Boutron, I. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355.","DOI":"10.1136\/bmj.i4919"},{"key":"ref_52","unstructured":"(2019, October 31). NIH Study Quality Assessment Tools n.d, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_53","unstructured":"Ryan, R. (2019, October 31). Group Cochrane Consumers and Communication Review. Cochrane Consumers and Communication Review Group: Data synthesis and analysis n.d. Available online: https:\/\/cccrg.cochrane.org\/."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:08Z","timestamp":1760177708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["antibiotics9100657"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9100657","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}